Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07559045 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

92

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy)
DRUG: Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)

Sponsor

Second Affiliated Hospital of Zunyi Medical University